| Literature DB >> 34336723 |
Renato Sathler-Avelar1,2,3,4, Danielle Marquete Vitelli-Avelar1,2, Armanda Moreira Mattoso-Barbosa3, Marcelo Antônio Pascoal-Xavier1, Silvana Maria Elói-Santos1,5, Ismael Artur da Costa-Rocha1, Andréa Teixeira-Carvalho1, Edward J Dick2, Jane F VandeBerg2, John L VandeBerg2,6,7, Olindo Assis Martins-Filho1.
Abstract
We performed a detailed analysis of immunophenotypic features of circulating leukocytes and spleen cells from cynomolgus macaques that had been naturally infected with Trypanosoma cruzi, identifying their unique and shared characteristics in relation to cardiac histopathological lesion status. T. cruzi-infected macaques were categorized into three groups: asymptomatic [CCC(-)], with mild chronic chagasic cardiopathy [CCC(+)], or with moderate chronic chagasic cardiopathy [CCC(++)]. Our findings demonstrated significant differences in innate and adaptive immunity cells of the peripheral blood and spleen compartments, by comparison with non-infected controls. CCC(+) and CCC(++) hosts exhibited decreased frequencies of monocytes, NK and NKT-cell subsets in both compartments, and increased frequencies of activated CD8+ T-cells and GranA+/GranB+ cells. While a balanced cytokine profile (TNF/IL-10) was observed in peripheral blood of CCC(-) macaques, a predominant pro-inflammatory profile (increased levels of TNF and IFN/IL-10) was observed in both CCC(+) and CCC(++) subgroups. Our data demonstrated that cardiac histopathological features of T. cruzi-infected cynomolgus macaques are associated with perturbations of the immune system similarly to those observed in chagasic humans. These results provide further support for the validity of the cynomolgus macaque model for pre-clinical research on Chagas disease, and provide insights pertaining to the underlying immunological mechanisms involved in the progression of cardiac Chagas disease.Entities:
Keywords: Trypanosoma cruzi; cardiac Chagas disease; cynomolgus macaques; cytokines; immune response; non-human primates
Mesh:
Year: 2021 PMID: 34336723 PMCID: PMC8317693 DOI: 10.3389/fcimb.2021.701930
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1Ex-vivo phenotypic signatures of peripheral blood leukocytes from T. cruzi-infected cynomolgus macaques classified according to histopathological features of chronic chagasic cardiopathy. The phenotypic signatures were constructed based on the proportion of subjects in each cell subpopulation with biomarker levels above the global median cut-off, calculated from data from the entire study population. Ascendant curves were assembled from non-infected controls (NI) to draw the reference curves for innate and adaptive immunity cells, used for comparative analysis of results from T. cruzi-infected cynomolgus macaques. Data are displayed by bar charts (NI = ) and continuous ascendant lines (NI = ○). The T. cruzi-infected macaques were classified according to histopathological features of cardiac biopsies and referred to as CCC(–) for absence of chronic chagasic cardiopathy (); CCC(+) for mild chronic chagasic cardiopathy () and CCC(++) for moderate chronic chagasic cardiopathy (). Comparative analyses between T. cruzi-infected subgroups and non-infected controls were carried out considering the ascendant biomarker signature of non-infected controls as the reference curve. The differences between groups were considered for biomarkers with proportions confined to distinct 50th percentiles as compared to the reference curve. The biomarkers with lower frequencies in T. cruzi-infected macaques were underscored by # and bold underline format. Those biomarkers with higher frequencies in T. cruzi-infected macaques were highlighted by *, bold underline format and color background.
Figure 2Ex-vivo phenotypic signatures of splenocytes from T. cruzi-infected cynomolgus macaques classified according to histopathological features of chronic chagasic cardiopathy. See legend to for details.
Phenotypic features of peripheral blood and spleen leukocytes from T. cruzi-infected cynomolgus macaques.
| Cell Phenotypes | Peripheral Blood | Spleen | ||||||
|---|---|---|---|---|---|---|---|---|
| NI | CCC(-) | CCC(+) | CCC(++) | NI | CCC(-) | CCC(+) | CCC(++) | |
| Innate Immunity | ||||||||
| CD14+CD32+ (MFI) | 304.8 ± 41.8 | 411.3 ± 59.7 | 445.8 ± 99.8 | 320.2 ± 72.7 | 459.4 ± 55.2 | 559.5 ± 67.8 | 475.3 ± 73.7 | 490.8 ± 19.2 |
| CD14+CD64+ (MFI) | 65.6 ± 9.0 | 92.1 ± 39.9 | 78.0 ± 21.0 | 41.8 ± 5.9 | 89.8 ± 11.2 | 102.6 ± 22.6 | 95.7 ± 26.1 | 91.8 ± 26.1 |
| CD3-CD16+ | 9.0 ± 2.0 | 4.9 ± 1.5 | 11.1 ± 3.2 | 12.4 ± 4.5 | 16.6 ± 4.6 | 12.3 ± 2.7 | 16.3 ± 5.9 | 15.8 ± 4.8 |
| %CD16+CD56- | 14.1 ± 3.4 |
| 10.8 ± 2.6 | 16.3 ± 6.0 | 27.7 ± 7.7 | 21.8 ± 5.0 | 28.9 ± 11.7 | 34.5 ± 6.8 |
| %CD16+CD56+ | 5.9 ± 1.4 | 6.1 ± 3.8 | 7.6 ± 2.9 | 10.8 ± 4.4 | 3.4 ± 0.4 | 5.9 ± 1.3 | 4.4 ± 0.4 | 4.3 ± 0.4 |
| %CD16-CD56+ | 6.2 ± 0.6 | 6.4 ± 1.2 | 6.9 ± 2.4 | 5.2 ± 1.1 | 5.5 ± 0.3 | 7.7 ± 0.9 | 7.2 ± 1.2 | 4.1 ± 0.5 |
| %CD16+CD54+ | 8.8 ± 1.7 | 15.6 ± 4.0 | 7.6 ± 3.8 | 8.3 ± 2.7 | 16.1 ± 2.4 | 26.5 ± 4.5 | 12.9 ± 5.7 | 13.5 ± 1.8 |
| %CD16+CD69+ | 35.5 ± 5.9 |
| 34.8 ± 6.0 | 26.5 ± 7.5 | 32.3 ± 2.8 | 32.3 ± 4.1 | 43.2 ± 8.7 | 29.6 ± 9.3 |
| %CD16+GranA+ | 16.6 ± 3.6 |
|
|
| 22.0 ± 2.5 | 21.1 ± 3.1 | 33.0 ± 7.8 | 37.5 ± 5.3 |
| %CD16+GranB+ | 45.7 ± 3.9 | 36.1 ± 5.8 | 45.4 ± 12.4 | 47.0 ± 9.2 | 59.1 ± 3.6 | 34.5 ± 3.0 | 52.6 ± 6.1 | 53.1 ± 6.6 |
| %CD16+Perf+ | 46.1 ± 6.6 | 37.8 ± 4.0 | 52.0 ± 9.1 | 46.9 ± 6.5 | 60.9 ± 3.7 | 31.9 ± 2.4 | 54.9 ± 5.4 | 52.8 ± 6.2 |
| CD3+CD16+ | 3.5 ± 0.4 | 4.2 ± 0.1 |
|
| 7.3 ± 0.9 | 8.2 ± 0.6 | 7.1 ± 1.2 | 4.7 ± 0.4 |
| % CD3+CD16+CD56- | 2.6 ± 0.7 |
| 0.9 ± 0.1 | 1.7 ± 0.6 | 5.0 ± 0.6 | 4.6 ± 1.2 | 5.2 ± 0.6 | 5.5 ± 1.7 |
| % CD3+CD16+CD56+ | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.4 ± 0.2 | 1.3 ± 0.2 | 1.2 ± 0.2 | 1.5 ± 0.6 | 1.2 ± 0.3 |
| % CD3+CD16-CD56+ | 3.6 ± 0.3 |
| 3.6 ± 0.7 | 2.7 ± 0.4 | 6.3 ± 0.7 | 6.9 ± 0.9 | 4.9 ± 0.4 | 3.8 ± 1.1 |
| Adaptive Immunity | ||||||||
| CD3+ | 62.0 ± 3.4 | 60.5 ± 3.1 | 58.1 ± 7.0 | 64.0 ± 5.2 | 54.6 ± 4.6 | 64.1 ± 2.6 | 51.6 ± 6.7 | 51.1 ± 6.0 |
| CD3+CD4+ | 32.7 ± 2.5 |
|
|
| 16.2 ± 1.8 | 13.7 ± 2.5 | 12.9 ± 1.6 | 16.7 ± 3.3 |
| CD3+CD8+ | 31.1 ± 3.3 | 37.4 ± 5.7 | 28.7 ± 8.7 | 35.9 ± 5.0 | 40.2 ± 4.3 | 38.1 ± 7.7 | 36.0 ± 5.7 | 33.6 ± 6.1 |
| %CD3+CD54+ | 1.0 ± 0.1 |
| 2.3 ± 1.0 | 1.4 ± 0.3 | 5.3 ± 0.8 | 4.6 ± 0.5 | 6.2 ± 1.6 | 3.3 ± 0.7 |
| %CD4+CD54+ | 1.4 ± 0.2 |
| 17.8 ± 15.7 | 6.9 ± 1.4 | 7.5 ± 1.0 | 9.5 ± 1.9 | 11.9 ± 4.4 | 6.4 ± 1.4 |
| %CD8+CD54+ | 1.2 ± 0.2 |
|
|
| 3.9 ± 0.5 | 4.1 ± 0.9 | 4.2 ± 0.9 | 3.2 ± 0.7 |
| %CD3+CD69+ | 9.6 ± 1.9 | 8.5 ± 2.8 | 9.7 ± 1.9 | 5.7 ± 1.6 | 26.1 ± 2.8 | 26.5 ± 3.2 | 36.0 ± 3.0 | 31.7 ± 4.2 |
| %CD4+CD69+ | 4.2 ± 1.0 | 4.5 ± 1.5 | 4.3 ± 1.5 | 3.2 ± 0.7 | 25.5 ± 2.1 | 30.0 ± 3.6 | 34.6 ± 1.6 | 28.7 ± 2.7 |
| %CD8+CD69+ | 23.1 ± 4.0 | 16.1 ± 2.5 |
| 16.1 ± 2.5 | 24.3 ± 2.5 | 27.0 ± 5.2 | 36.3 ± 2.1 | 30.2 ± 4.9 |
| %CD3+HLA-DR+ | 3.1 ± 0.7 |
|
| 3.0 ± 0.3 | 6.6 ± 0.8 | 9.0 ± 0.6 | 8.3 ± 1.1 | 11.0 ± 1.4 |
| %CD4+HLA-DR+ | 3.1 ± 0.4 | 4.6 ± 1.3 | 3.9 ± 0.6 |
| 18.1 ± 1.7 | 20.6 ± 5.3 | 19.5 ± 4.4 | 17.4 ± 3.0 |
| %CD8+HLA-DR+ | 5.6 ± 1.8 | 7.7 ± 1.8 | 7.8 ± 1.4 | 6.5 ± 1.6 | 6.8 ± 0.9 | 7.3 ± 1.8 | 6.3 ± 1.9 | 10.4 ± 1.6 |
| %CD3+CCR5+ | 26.4 ± 4.6 | 29.2 ± 7.5 | 28.7 ± 2.7 | 20.6 ± 5.9 | 33.0 ± 4.0 | 39.6 ± 9.1 | 29.1 ± 6.0 | 30.0 ± 5.9 |
| %CD4+CCR5+ | 19.7 ± 2.9 | 24.8 ± 4.6 | 16.3 ± 1.2 | 17.5 ± 3.8 | 34.6 ± 2.7 | 48.7 ± 6.8 | 30.2 ± 2.8 | 29.7 ± 4.9 |
| %CD8+CCR5+ | 31.6 ± 5.5 | 34.5 ± 7.3 | 38.0 ± 4.5 | 25.3 ± 7.5 | 30.6 ± 3.7 | 41.8 ± 8.0 | 25.8 ± 5.5 | 23.2 ± 4.8 |
| %CD8+GranA+ | 6.9 ± 4,5 |
|
|
| 11.0 ± 1.9 | 11.2 ± 2.6 | 14.9 ± 1.7 | 17.5 ± 1.9 |
| %CD8+GranB+ | 52.6 ± 7.2 | 58.2 ± 11.9 | 49.0 ± 9.1 | 55.9 ± 7.4 | 43.6 ± 5.5 | 43.6 ± 8.5 | 38.8 ± 8.7 | 46.8 ± 3.8 |
| %CD8+Perf+ | 56.2 ± 7.9 | 69.1 ± 11.0 | 62.7 ± 8.1 | 63.3 ± 8.0 | 58.4 ± 6.6 | 61.3 ± 9.6 | 58.1 ± 9.1 | 57.6 ± 6.1 |
| %CD4+CD25++ | 3.5 ± 0.3 | 4.1 ± 0.5 | 4.1 ± 0.5 | 4.3 ± 0.3 | 2.4 ± 0.4 | 3.0 ± 0.6 | 2.7 ± 0.7 | 3.8 ± 0.7 |
| CD20+ | 22.4 ± 4.7 | 27.1 ± 3.5 | 28.7 ± 6.3 | 19.9 ± 4.5 | 22.4 ± 4.5 | 19.6 ± 2.7 | 20.0 ± 6.7 | 26.8 ± 6.4 |
| %CD20+CD69+ | 2.6 ± 0.4 | 3.5 ± 1.1 | 3.3 ± 0.5 | 2.6 ± 1.2 | 13.9 ± 1.8 | 13.2 ± 2.2 | 19.5 ± 2.9 | 13.5 ± 2.7 |
| CD20+CD32+ (MFI) | 56.2 ± 7.5 | 84.9 ± 15.5 | 71.2 ± 17.9 | 66.0 ± 11.3 | 72.2 ± 13.6 | 126.6 ± 13.8 | 65.2 ± 12.2 | 87.5 ± 13.4 |
NI, Non-infected macaques; CCC(-), Absence of Chronic Chagasic Cardiopathy; CCC(+), Mild Chronic Chagasic Cardiopathy; CCC(++), Moderate Chronic Chagasic Cardiopahty. Data are expressed as mean values (% or mean fluorescence intensity-MFI) standard error. Multiple comparisons amongst groups were carried out by Kruskal-Wallis test followed by Dunn’s post-test for sequential pairwise comparisons and significant differences at p < 0.05 depicted by letters “a”, “b”, “c” and “d” as compared to NI, CCC(-), CCC(+) and CCC(++), respectively. All significant differences are highlighted in bold format.
Ex vivo cytokine profile of peripheral blood leukocytes from T. cruzi-infected cynomolgus macaques.
| Cell Phenotypes | Peripheral Blood | |||
|---|---|---|---|---|
| NI | CCC(-) | CCC(+) | CCC(++) | |
| Innate Immunity | ||||
| TNF+CD14+ | 24.6 ± 5.5 | 31.6 ± 4.7 | 31.9 ± 10.2 |
|
| TNF+CD14+CD16+DR++ | 71.0 ± 46 | 60.8 ± 24.6 | 69.1 ± 7.8 | 61.8 ± 17.1 |
| TNF+CD16+ | 12.0 ± 5.1 | 13.1 ± 4.0 |
| 7.6 ± 2.0 |
| IFN+CD16+ | 17.6 ± 5.3 | 14.7 ± 2.5 | 14.1 ± 4.5 | 14.7 ± 3.1 |
| IL-10+CD14+ | 31.3 ± 8.6 | 27.0 ± 8.2 | 24.4 ± 3.4 | 22.2 ± 4.8 |
| IL-10+CD14+CD16+DR++ | 29.8 ± 8.2 | 27.1 ± 1.1 |
| 37.5 ± 7.8 |
| Adaptive Immunity | ||||
| TNF+CD4+ | 6.8 ± 1.4 | 7.5 ± 1.9 | 4.5 ± 1.6 | 7.0 ± 1.5 |
| TNF+CD8+ | 4.9 ± 1.0 | 4.5 ± 0.7 | 3.0 ± 1.0 |
|
| TNF+CD20+ | 7.6 ± 1.4 | 7.3 ± 1.8 | 7.3 ± 2.2 |
|
| IFN+CD4+ | 4.8 ± 0.7 |
|
|
|
| IFN+CD8+ | 5.0 ± 1.0 | 2.8 ± 0.7 | 3.5 ± 1.1 |
|
| IL-10+CD4+ | 6.5 ± 2,4 |
|
|
|
| IL-10+CD8+ | 15.1 ± 2.9 | 9.7 ± 2.6 |
|
|
| IL-10+CD20+ | 25.0 ± 8.7 | 23.4 ± 3.0 | 24.7 ± 6.6 |
|
NI, Non-infected macaques; CCC(-), Absence of Chronic Chagasic Cardiopathy; CCC(+), Mild Chronic Chagasic Cardiopathy; CCC(++), Moderate Chronic Chagasic Cardiopahty. Data are expressed as mean values (‰) ± standard error. Multiple comparisons amongst groups were carried out by Kruskal-Wallis test followed by Dunn’s post-test for sequential pairwise comparisons and significant differences at p<0.05 depicted by letters “a”, “b”, “c” and “d” as compared to NI, CCC(-), CCC(+) and CCC(++), respectively. All significant differences are highlighted in bold format.
Figure 3Ex vivo cytokine signatures of peripheral blood leukocytes from T. cruzi-infected cynomolgus macaques classified according to histopathological features of chronic chagasic cardiopathy. The functional cytokine signatures were constructed based on the proportion of subjects with intracytoplasmic cytokine levels above the global median cut-off defined for each cell subset, calculated for the entire study population. Radar charts were built to obtain the overall profile of pro-inflammatory (left side) and regulatory (right side) cytokines for innate and adaptive immunity cells. Distinct color backgrounds were used to tag the non-infected controls (NI = ) and the subgroups of T. cruzi-infected cynomolgus macaques, classified according to histopathological features of cardiac biopsies and referred to as CCC(–) for absence of chronic chagasic cardiopathy (); CCC (+) for mild chronic chagasic cardiopathy () and CCC (++) for moderate chronic chagasic cardiopathy (). The biomarkers with frequencies above the 50th percentile were highlighted for each group by bold underline format.
Figure 4Set of phenotypic/functional biomarkers useful to depict the cardiac lesion status in T. cruzi-infected cynomolgus macaques. (A) Venn diagram analyses were carried out to identify common and selective phenotypic biomarkers in peripheral blood and spleen samples from T. cruzi-infected cynomolgus macaques (CH = ) and non-infected controls (NI = ), and subsequently among subgroups of T. cruzi-infected macaques, classified according to histopathological features of cardiac biopsies and referred as CCC (–) for absence of chronic chagasic cardiopathy (); CCC (+) for mild chronic chagasic cardiopathy () and CCC (++) for moderate chronic chagasic cardiopathy (). (B) Venn diagram analyses were performed to select, within the intracytoplasmic cytokine profile of peripheral blood leukocytes upon TcI-Ag recall in vitro, the common and unique functional biomarkers for T. cruzi-infected cynomolgus macaques (CH) and non-infected controls (NI) and subsequently among the CCC (–), CCC (+) and CCC (++) groups. The selected sets of biomarkers are shown in the figure. Detailed data and conventional statistical analysis is presented in .